Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nefazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nefazodone SCHEMBL29375893 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL6479060 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL27748022 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL30054492 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL27748020 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL5501519 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL8195097 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL41119 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL9275261 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL7659683 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23239 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| US-12564590-B2 | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | SYNDAX PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-0668857-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLONE COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1995-08-30 | — | — | EP | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| WO-1994011357-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLONE COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO (A.C.R.A.F.) S.P.A. (IT) | 1994-05-26 | — | — | WO | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0493687-A2 | Treatment of sleep disorders using certain anti-depressants, e.g. nefazodone | Bristol-Myers Squibb Company (US) | 1992-07-08 | — | — | EP | claimed |
| US-5116852-A | TREATMENT OF SLEEP DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1992-05-26 | — | — | US | claimed |
| EP-0337050-A1 | Process and apparatus for the partial or total demineralisation of water | CILLIT WASSERTECHNIK GMBH & CO. (DE) | 1989-10-18 | — | — | EP | claimed |
| EP-0227051-A2 | Heat pump installation with a heat source for heating and distributing of heating and/or sanitary hot water | Gössi, Hans (CH) | 1987-07-01 | — | — | EP | claimed |
| US-4338317-A | Phenoxyethyl-1,2,4,-triazol-3-one antidepressants | MEAD JOHNSON & COMPANY (US) | 1982-07-06 | — | — | US | claimed |